Evidence map›Paper›PMID 30411203›Full record

ArticleInfectious diseases and therapy2018

Response to McGirr et al.'s Comment on "Clinical and Economic Impact of a Potential Switch from 13-Valent to 10-Valent Pneumococcal Conjugate Infant Vaccination in Canada".

Michele R Wilson, Matt Wasserman, Taj Jadavji, Maarten Postma, Marie-Claude Breton, Francois Peloquin, Stephanie R Earnshaw, Cheryl McDade, Heather L Sings, Raymond Farkouh

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Infectious diseases and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michele R WilsonRTI Health Solutions, Research Triangle Park, NC, USA. mwilson@rti.org.
Matt WassermanPfizer Inc., New York, NY, USA.
Taj JadavjiDepartments of Pediatrics, Microbiology, Immunology, and Infectious Diseases, Faculty of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Canada.
Maarten PostmaDepartment of Pharmacy, University of Groningen, Groningen, The Netherlands.
Marie-Claude BretonPfizer Canada Inc., Kirkland, QC, Canada.
Francois PeloquinPfizer Canada Inc., Kirkland, QC, Canada.
Stephanie R EarnshawRTI Health Solutions, Research Triangle Park, NC, USA.
Cheryl McDadeRTI Health Solutions, Research Triangle Park, NC, USA.
Heather L SingsPfizer Inc., Collegeville, PA, USA.
Raymond FarkouhPfizer Inc., Collegeville, PA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Cost-effectivenessHealth economicsPneumococcal diseaseVaccination

Identifiers

PMID30411203
PMCPMC6249185

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.